CHRS R&D to Revenue
Coherus Oncology Inc · R&D to Revenue
CHRS R&D to Revenue
Latest reported248.90%period ending
CHRS FY R&D/Revenue (1837.07% → 248.90%)
Latest values, visible window
High-resolution chart · PNG
CHRS r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 248.895% | |
| 34.9625% | |
| 42.5417% | |
| 94.4637% | |
| 111.194% | |
| 30.0025% | |
| 26.452% | |
| 7,084.7686% | |
| 10,436.3111% | |
| 133.8411% | |
| 709.2374% | |
| 251.4756% | |
| 1,137.0047% | |
| 1,837.0721% |